Manager × security

Bain Capital Life Sciences Investors, LLC NAMS holdings history

NEWAMSTERDAM PHARMA CO NV · CUSIP N62509109 · CIK 1703031

This is the oldest quarter open without an account, so changes against the quarter before it are withheld. Sign in to see them.
Citable facts

As of 2026-06-30, Bain Capital Life Sciences Investors, LLC reported 3.81M NAMS (shares), valued at $129.00M, or 7.67% of its reported non-derivative portfolio. Filed 2026-08-14.

Verify history & sources →
Portfolio weight and quantity history
Reported portfolio weight
7.67%
Shares
3.81M
3,806,566
Reported value
$129.00M
USD

Shares decreased 47.90%; reported value decreased 44.84%, and weight changed -13.42 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.

Left: % · Right: Shares · Independently scaled axes

Exact data and methodology

Axes scale independently; a crossing does not mean equal values. Weight uses each quarter's total reported non-derivative value. Same CUSIP; missing quarters are gaps, not zero. Revised history may include later disclosures.

QuarterWeightQuantitySource
Q2 20267.67%3,806,566SEC filing ↗Filed Aug 14, 2026
Q1 202621.09%7,306,566SEC filing ↗Filed May 15, 2026
Q4 202519.63%7,306,566SEC filing ↗Filed Feb 17, 2026
Q3 202520.23%10,719,110SEC filing ↗Filed Nov 14, 2025
Q2 202524.29%10,719,110SEC filing ↗Filed Aug 14, 2025
Q1 202532.46%10,719,110SEC filing ↗Filed May 15, 2025
Q4 202432.41%10,719,110SEC filing ↗Filed Feb 14, 2025
Q3 202418.09%10,473,913SEC filing ↗Filed Nov 14, 2024
Q2 202422.09%10,473,913SEC filing ↗Filed Aug 12, 2024
Q1 202419.91%10,473,913SEC filing ↗Filed May 15, 2024
Q4 202311.21%10,473,913SEC filing ↗Filed Feb 13, 2024

History & evidence by quarter

QuarterWeightQuantityValueChange explainedSource
Q4 202311.21%10,473,913$116.99MThe prior quarter is outside the free window. Sign in for the comparison.SEC filing ↗
Filed Feb 13, 2024
Q1 202419.91%10,473,913$247.71MShares unchanged; reported value increased 111.73%, and weight changed +8.70 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2024
Q2 202422.09%10,473,913$201.20MShares unchanged; reported value decreased 18.77%, and weight changed +2.18 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 12, 2024
Q3 202418.09%10,473,913$173.87MShares unchanged; reported value decreased 13.59%, and weight changed -4.00 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 14, 2024
Q4 202432.41%10,719,110$275.48MShares increased 2.34%; reported value increased 58.44%, and weight changed +14.32 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 14, 2025
Q1 202532.46%10,719,110$219.42MShares unchanged; reported value decreased 20.35%, and weight changed +0.05 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2025
Q2 202524.29%10,719,110$194.12MShares unchanged; reported value decreased 11.53%, and weight changed -8.17 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 14, 2025
Q3 202520.23%10,719,110$304.85MShares unchanged; reported value increased 57.04%, and weight changed -4.06 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 14, 2025
Q4 202519.63%7,306,566$256.31MShares decreased 31.84%; reported value decreased 15.92%, and weight changed -0.60 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 17, 2026
Q1 202621.09%7,306,566$233.88MShares unchanged; reported value decreased 8.75%, and weight changed +1.46 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2026
Q2 20267.67%3,806,566$129.00MShares decreased 47.90%; reported value decreased 44.84%, and weight changed -13.42 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 14, 2026
Bain Capital Life Sciences Investors, LLC · NEWAMSTERDAM PHARMA CO NV

Take these holdings further.

This page includes 11 of 11 reported holdings. Sign in to look up the full history beyond 3 years, use advanced screening & filtering, download CSV, and get the complete set through the Akkru API.

  • Download CSV
  • Earlier quarters
  • Advanced screening & filtering
  • API & AI access
Already have an account?

+ New accounts get free API credits to explore data beyond ownership filings.

For AI agents & developers

The initial HTML of this page carries its exact data as script#research-data (JSON): values, units, scope, preview limits and SEC sources. Read it directly, no script or API key needed; script#research-access says what needs an account.

Without an account: the last 3 years, with the row caps stated on the page. A free account opens all history on file on these pages and the CSV of what a page shows. Rows beyond the caps and bulk retrieval go through the authenticated API / MCP.

MCP  https://api.akkrudata.ai/mcp

get_institutional_portfolio
{"cik":"1703031","quarter":"2026Q2","cusip":"N62509109"}

get_institutional_manager_history
{"cik":"1703031","page_size":100}

Connect to MCP with OAuth and follow the returned pagination. Credits and usage limits depend on the account.

MCP endpoint
https://api.akkrudata.ai/mcp
API / MCP documentation
/documents
llms.txt
/llms.txt
Sources, coverage & how to read this data

Figures are as reported to the SEC and merged with later amendments where Akkru could match them. Preview limits apply to what is listed, not to the totals, which come from the complete reported data. Nothing is zero-filled: a missing quarter or month is shown as missing.

13F reports quarter-end long positions in securities traded on US exchanges, filed by managers holding at least $100 million of such securities; it is not the manager's full portfolio, not assets under management, and value changes are not returns. Weights use the reported total value as denominator. Option rows show notional value, not premium or net exposure. Amendments are merged into the quarter when Akkru could match them.